LAUSR

Pranlukast is a potent selective cysteniyl leukotriene receptor antagonist to treat bronchial asthma and allergic rhinitis, which exists in several crystal forms. In this work, solution-mediated phase transformation process from Pranlukast DMF solvate to the hemihydrate form was studied by using the focused beam reflectance measurement probe combined with powder X-ray diffraction. The influence factors such as temperature, solvent composition, amount of added solid, and stirring rate were investigated. Results showed that higher temperature, larger mole fraction of water, lower amount of added solid, and faster stirring rate could accelerate the solution-mediated phase transformation process.